FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4310348454> ?p ?o ?g. }

• W4310348454 endingPage "3972" @default.
• W4310348454 startingPage "3959" @default.
• W4310348454 abstract "To analyze the use of artificial tears in patients undergoing treatment with anti-vascular endothelial growth (anti-VEGF) intravitreal injections.Thirty-four eyes undergoing anti-VEGF treatment were analyzed. Each patient underwent a subjective and objective evaluation of the ocular surface, using the Ocular Surface Disease Index (OSDI), Dry Eye Questionnaire (DEQ)-5, tear meniscus height (TMH), first and average non-invasive Keratograph Break-Up Time (NIKBUT), bulbar conjunctival redness, meibography and the Vision Break-Up Time (VBUT). Patients attended 5 visits (days 0, 7, 30, 37, and 60). All patients continued with their intravitreal injection treatment during the study (days 0, 30, and 60). Patients did not receive any artificial tear treatment during the first month of the study, and at the baseline visit they were randomly assigned to one of two study groups to receive either the Systane Hydration or the Viscofresh 10mg/mL formulation. Patients were instructed to instill one drop of the assigned study treatment 3 times a day for 30 days during the second month of the study.According to the Mixed Models for Repeated Measures analysis, there is not enough statistical evidence for any of the parameters examined to determine significant differences between being treated with artificial tears and not being treated (p > 0.05). There is, however, a tendency toward improved outcomes in some parameters when artificial tears were used. OSDI, DEQ-5, TMH, and meibography were not affected by either the type of artificial tear used or by the time (from day 30 to day 60; p > 0.05), but the NIKBUT and VBUT values increased over time during this period regardless of which treatment the patient was receiving.The use of artificial tears may help to keep the tear film stable Future studies with larger samples should be conducted to elucidate whether the tendency reported in our study becomes significant." @default.
• W4310348454 created "2022-12-09" @default.
• W4310348454 creator A5009076515 @default.
• W4310348454 creator A5039323161 @default.
• W4310348454 creator A5083774543 @default.
• W4310348454 creator A5083908295 @default.
• W4310348454 creator A5091179553 @default.
• W4310348454 date "2022-11-01" @default.
• W4310348454 modified "2023-09-26" @default.
• W4310348454 title "Use of Artificial Tears in Patients Undergoing Treatment with Anti-VEGF Intravitreal Injections" @default.
• W4310348454 cites W1902102829 @default.
• W4310348454 cites W1981706451 @default.
• W4310348454 cites W1984864129 @default.
• W4310348454 cites W1989291233 @default.
• W4310348454 cites W2091630088 @default.
• W4310348454 cites W2133606314 @default.
• W4310348454 cites W2173077928 @default.
• W4310348454 cites W2227017764 @default.
• W4310348454 cites W2339286115 @default.
• W4310348454 cites W2419523617 @default.
• W4310348454 cites W2519403553 @default.
• W4310348454 cites W2547255159 @default.
• W4310348454 cites W2586227287 @default.
• W4310348454 cites W2596391620 @default.
• W4310348454 cites W2903164967 @default.
• W4310348454 cites W2918101236 @default.
• W4310348454 cites W2953442232 @default.
• W4310348454 cites W2984966565 @default.
• W4310348454 cites W2989989541 @default.
• W4310348454 cites W2990343807 @default.
• W4310348454 cites W3126219427 @default.
• W4310348454 cites W3163274996 @default.
• W4310348454 cites W2979391666 @default.
• W4310348454 doi "https://doi.org/10.2147/opth.s391082" @default.
• W4310348454 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36474999" @default.
• W4310348454 hasPublicationYear "2022" @default.
• W4310348454 type Work @default.
• W4310348454 citedByCount "0" @default.
• W4310348454 crossrefType "journal-article" @default.
• W4310348454 hasAuthorship W4310348454A5009076515 @default.
• W4310348454 hasAuthorship W4310348454A5039323161 @default.
• W4310348454 hasAuthorship W4310348454A5083774543 @default.
• W4310348454 hasAuthorship W4310348454A5083908295 @default.
• W4310348454 hasAuthorship W4310348454A5091179553 @default.
• W4310348454 hasBestOaLocation W43103484541 @default.
• W4310348454 hasConcept C118487528 @default.
• W4310348454 hasConcept C126322002 @default.
• W4310348454 hasConcept C141071460 @default.
• W4310348454 hasConcept C167734588 @default.
• W4310348454 hasConcept C2778275304 @default.
• W4310348454 hasConcept C2778837293 @default.
• W4310348454 hasConcept C71924100 @default.
• W4310348454 hasConceptScore W4310348454C118487528 @default.
• W4310348454 hasConceptScore W4310348454C126322002 @default.
• W4310348454 hasConceptScore W4310348454C141071460 @default.
• W4310348454 hasConceptScore W4310348454C167734588 @default.
• W4310348454 hasConceptScore W4310348454C2778275304 @default.
• W4310348454 hasConceptScore W4310348454C2778837293 @default.
• W4310348454 hasConceptScore W4310348454C71924100 @default.
• W4310348454 hasLocation W43103484541 @default.
• W4310348454 hasLocation W43103484542 @default.
• W4310348454 hasLocation W43103484543 @default.
• W4310348454 hasLocation W43103484544 @default.
• W4310348454 hasOpenAccess W4310348454 @default.
• W4310348454 hasPrimaryLocation W43103484541 @default.
• W4310348454 hasRelatedWork W1529638560 @default.
• W4310348454 hasRelatedWork W1998054151 @default.
• W4310348454 hasRelatedWork W2060033748 @default.
• W4310348454 hasRelatedWork W2354640403 @default.
• W4310348454 hasRelatedWork W2395044421 @default.
• W4310348454 hasRelatedWork W2587436937 @default.
• W4310348454 hasRelatedWork W3029036527 @default.
• W4310348454 hasRelatedWork W3030537508 @default.
• W4310348454 hasRelatedWork W3041253394 @default.
• W4310348454 hasRelatedWork W4297850889 @default.
• W4310348454 hasVolume "Volume 16" @default.
• W4310348454 isParatext "false" @default.
• W4310348454 isRetracted "false" @default.
• W4310348454 workType "article" @default.